Patents by Inventor Todd Bowser

Todd Bowser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210395189
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.
    Type: Application
    Filed: January 4, 2021
    Publication date: December 23, 2021
    Inventors: Paul Abato, Todd Bowser
  • Publication number: 20210275503
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for its use, such as to treat cancer.
    Type: Application
    Filed: March 3, 2021
    Publication date: September 9, 2021
    Inventors: Thomas O'SHEA, Markus RENSCHLER, Todd BOWSER, Jean-Marc LAPIERRE, Kevin MILLS
  • Publication number: 20170305840
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: December 9, 2016
    Publication date: October 26, 2017
    Inventors: Mark L. Nelson, Kwasi Ohemeng, Paul Abato, Victor Amoo, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Oak K. Kim, Jude Mathews, Rachid Mechiche
  • Patent number: 9533943
    Abstract: The present invention pertains, at least in part, to novel substituted etracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: January 3, 2017
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Todd Bowser, Mark Grier
  • Patent number: 9365500
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: June 14, 2016
    Assignee: PARATEK PHARMACEUTICALS, INC.
    Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia
  • Publication number: 20160046561
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.
    Type: Application
    Filed: March 26, 2015
    Publication date: February 18, 2016
    Inventors: Paul Abato, Todd Bowser
  • Publication number: 20150174144
    Abstract: Tetracycline compounds for treating neurodegenerative disorders are disclosed herein. Also disclosed is a pharmaceutical composition comprising the tetracycline compounds, and a method for treating, preventing, or ameliorating neurodegenerative disorders or inflammation in a subject by administering the tetracycline compounds or a pharmaceutical composition thereof, either alone or in combination with a second therapeutic agent.
    Type: Application
    Filed: July 15, 2013
    Publication date: June 25, 2015
    Inventors: Todd Bowser, Paul Higgins, Michael P. Draper, S. Ken Tanaka
  • Publication number: 20150166470
    Abstract: 7-Disubstituted-phenyl tetracycline compounds are disclosed herein. Also disclosed is a method for treatment or prevention of spinal muscular atrophy using the 7-disubstituted-phenyl tetracycline compounds. This invention also relates to a method for treating or preventing a subject having spinal muscular atrophy. The method includes administering to the subject an effective amount of a tetracycline compound of formula (1), such that the spinal muscular atrophy is treated or prevented. Advantageously, the tetracycline compounds used in this method of the invention have one or more of the following characteristics: 1) potency in modulating mRNA splicing, 2) potency in modulating SMN protein levels, 3) central nervous system (CNS) and/pr brain penetration, 4) decreased phototoxic properties and 5) decreased antibacterial properties.
    Type: Application
    Filed: May 30, 2013
    Publication date: June 18, 2015
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Todd Bowser, Paul Abato
  • Patent number: 9012433
    Abstract: The present invention pertains to tetracycline compounds of formula (VIIa): R5*, R5*?, R7r*, and R9m* are defined herein. These tetracycline compounds can be used to treat tetracycline compound-responsive states, such as multiple sclerosis and rheumatoid arthritis.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: April 21, 2015
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Paul Abato, Todd Bowser
  • Publication number: 20150045329
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: May 19, 2014
    Publication date: February 12, 2015
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Kwasi Ohemeng, Paul Abato, Victor Amoo, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Oak K. Kim, Jude Mathews, Rachid Mechiche
  • Publication number: 20140309199
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 16, 2014
    Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia
  • Publication number: 20140155357
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: June 14, 2013
    Publication date: June 5, 2014
    Inventors: Paul Abato, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng, Jingwen Pan
  • Patent number: 8492365
    Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: July 23, 2013
    Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
  • Patent number: 8466132
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: June 18, 2013
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Paul Abato, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng, Jingwen Pan
  • Patent number: 8399437
    Abstract: Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: March 19, 2013
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Joel Berniac, Todd Bowser, Michael P. Draper, Stuart B. Levy, Mark L. Nelson
  • Publication number: 20120283201
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: July 12, 2012
    Publication date: November 8, 2012
    Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell J. Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhalie, Atul K. Verma, Laura Honeyman, Tadeusz Warchol, David Messersmith
  • Patent number: 8048867
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: November 1, 2011
    Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell J. Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhatia, Atul K. Verma, Laura McIntyre, Tadeusz Warchol, David Messersmith
  • Publication number: 20110230523
    Abstract: Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.
    Type: Application
    Filed: August 6, 2009
    Publication date: September 22, 2011
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Stuart B. LEVY, Michael N. ALEKSHUN, Brent L. PODLOGAR, Kwasi OHEMENG, Atul K. VERMA, Tadeusz WARCHOL, Beena BHATIA, Todd BOWSER, Mark GRIER
  • Publication number: 20110207706
    Abstract: Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.
    Type: Application
    Filed: May 3, 2011
    Publication date: August 25, 2011
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Joel Berniac, Todd Bowser, Michael Draper, Stuart B. Levy, Mark L. Nelson
  • Patent number: 7935687
    Abstract: Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: May 3, 2011
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Joel Berniac, Todd Bowser, Michael Draper, Stuart B. Levy, Mark L. Nelson